University Health Network, Toronto: Carcinoma, Ovarian Epithelial trials

The registry lists 14 Carcinoma, Ovarian Epithelial studies with University Health Network, Toronto as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 8No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
• Erdafitinib in Metastatic Steroid-cell Ovarian CancerCompletedNCT06328491Not applicable
• 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)CompletedNCT03811899Not applicable
• A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian CancerCompletedNCT03081702Phase 1/2
• Ovarian Tumor Biopsies to Study Response to TreatmentsCompletedNCT02952521
• Study of Azacitidine and Durvalumab in Advanced Solid TumorsCompletedNCT02811497Phase 2
• A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
• Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
• A Study of Long-Term Responders on OlaparibCompletedNCT02489058
• Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.TerminatedNCT02341118
• A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
• Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel ObstructionTerminatedNCT01083537Phase 1/2
• Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian CancerTerminatedNCT00889733Phase 1/2
• UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00072267Phase 2